IVVD · Invivyd, Inc.
$0.72
+0.04 (+5.13%)
At close · Aug 14
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on current operating plans and excluding future external financing, we will not have sufficient cash and cash equivalents to fund our operating expenses and capital requirements beyond one year from the issuance date of the condensed consolidated financial statements in this Quarterly Report on Form 10-Q, and therefore, we have concluded that there is substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Market Cap
$212.49M
Shares
294.76M
Invivyd, Inc. Earnings Call Transcripts
Every quarterly earnings call for Invivyd, Inc. (IVVD) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
·
$
−$50.23M
'23 Q2
23-08-10
·
$
−$39.44M
'23 Q3
23-11-09
·
$
−$43.50M
'24 Q1
24-05-09
·
$2.26M
−$47.25M
'24 Q2
24-08-14
·
$9.30M
−$60.74M
'24 Q3
24-11-14
·
$13.82M
−$18.44M
'24 Q4
25-02-03
·
$11.30M
−$16.29M
'25 Q1
25-05-15
▲41.2%
$13.13M
−$10.47M
'25 Q3
25-11-06
▲24.5%
$17.21M
−$11.07M
'25 Q4
26-03-05
▲21.6%
$13.74M
−$41.40M
'26 Q1
26-05-14
LATEST
▲21.2%
$14.29M
−$44.39M
'26 Q2
26-08-13
Earnings call
FY26 · Q2
2026-08-13
Invivyd, Inc. Q2 FY2026 Earnings Call
Revenue
$14.29M
▲ 21.2% YoY Diluted EPS
$-0.14
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-03
2026 Jefferies Global Healthcare Conference in New York
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-14
Invivyd, Inc. Q1 FY2026 Earnings Call
Confident tone
Public education and messaging
Monoclonal antibody platform strategy
Pivotal program recruitment and timing
Revenue
$13.74M
▲ 21.6% YoY Diluted EPS
$-0.13
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-04-09
Invivyd Revolution Program & Measles Update Conference Call
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q4
2026-03-05
Invivyd, Inc. Q4 FY2025 Earnings Call
Positive tone
VYD-2311 COVID Prophylaxis Program
Pemgarda Commercial Performance
RSV Antibody Program
Revenue
$17.21M*
▲ 24.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Invivyd, Inc. Q3 FY2025 Earnings Call
Confident tone
VYD2311 pivotal program
Discovery pipeline (RSV, nasal antibodies, measles)
PEMGARDA commercial franchise
Revenue
$13.13M
▲ 41.2% YoY Diluted EPS
$-0.06
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2025-10-30
Invivyd REVOLUTION Pivotal Program Conference Call
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q1
2025-05-15
Invivyd, Inc. Q1 FY2025 Earnings Call
Confident tone
SARS-CoV-2 epitope durability
Regulatory strategy and EUA-to-BLA path
PEMGARDA commercial transition and growth
Revenue
$11.30M
Diluted EPS
$-0.14
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-03
Invivyd, Inc. Q4 FY2024 Earnings Call
Revenue
$13.82M*
Rev · 5q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-14
Invivyd, Inc. Q3 FY2024 Earnings Call
Cautious tone
FDA/regulatory headwind and KP.3.1.1 susceptibility issue
Pemivibart (PEMGARDA) clinical efficacy and CANOPY data
Treatment EUA / immunobridging regulatory pathway
Revenue
$9.30M
Diluted EPS
$-0.51
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-14
Invivyd, Inc. Q2 FY2024 Earnings Call
Positive tone
Immunocompromised patient population and unmet need
PEMGARDA commercial launch and net revenue
Pipeline molecule VYD2311
Revenue
$2.26M
Diluted EPS
$-0.40
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Invivyd, Inc. Q1 FY2024 Earnings Call
Confident tone
PEMGARDA commercial launch
Treatment opportunity and competition
Regulatory pathway and FDA alignment
Revenue
$
Diluted EPS
$-0.38
Rev · 3q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-25
Invivyd, Inc. Q4 FY2023 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-09
Invivyd, Inc. Q3 FY2023 Earnings Call
Revenue
$
Diluted EPS
$-0.36
Rev · 2q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-10
Invivyd, Inc. Q2 FY2023 Earnings Call
Revenue
$
Diluted EPS
$-0.46
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-11
Invivyd, Inc. Q1 FY2023 Earnings Call
Diluted EPS
$-0.32
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-23
Invivyd, Inc. Q4 FY2022 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-10
Invivyd, Inc. Q3 FY2022 Earnings Call
Diluted EPS
$-0.42
Audio
Transcript
Slides
8-K10-Q
Showing 1–18 of 18 earnings calls
Key facts
CIK
1832038
CUSIP
00534A102
13F (30d)
128 filings
125 filers
Visit website
Investor relations